Joseph Thome
Stock Analyst at TD Cowen
(4.89)
# 289
Out of 4,675 analysts
419
Total ratings
58.1%
Success rate
25.9%
Average return
Main Sectors:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintained: Buy | $675 | $512.88 | +31.61% | 31 | Aug 24, 2026 | |
| ANAB AnaptysBio | Maintained: Buy | $75 → $70 | $58.44 | +19.78% | 25 | Aug 24, 2026 | |
| AMLX Amylyx Pharmaceuticals | Maintained: Buy | n/a | $38.15 | - | 8 | Aug 18, 2026 | |
| DRUG Bright Minds Biosciences | Maintained: Buy | n/a | $77.03 | - | 9 | Aug 16, 2026 | |
| NGEN NervGen Pharma | Maintained: Buy | n/a | $2.00 | - | 2 | Aug 13, 2026 | |
| MGX Metagenomi Therapeutics | Maintained: Buy | n/a | $1.21 | - | 13 | Aug 11, 2026 | |
| AXSM Axsome Therapeutics | Maintained: Buy | $300 → $315 | $205.40 | +53.36% | 35 | Aug 10, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintained: Buy | $140 | $96.72 | +44.75% | 10 | Aug 10, 2026 | |
| ARDX Ardelyx | Maintained: Buy | $13 → $10 | $3.74 | +167.38% | 22 | Aug 6, 2026 | |
| VRDN Viridian Therapeutics | Maintained: Buy | n/a | $24.02 | - | 17 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $60.56 | - | 17 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $24.20 | - | 5 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $90 | $86.73 | +3.30% | 8 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $275 → $300 | $254.47 | +17.89% | 29 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $90 | $71.06 | +26.65% | 47 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $47.46 | - | 27 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $57 → $58 | $48.87 | +18.68% | 21 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $25.99 | - | 2 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $49.33 | - | 16 | Jul 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $12.56 | - | 21 | Jun 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $11.36 | - | 2 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $7.33 | - | 15 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.25 | - | 10 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.66 | - | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $21.33 | n/a | 9 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0001 | n/a | 5 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $40 | $154.31 | n/a | 1 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $12.01 | n/a | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $145.75 | n/a | 1 | Oct 1, 2020 |
United Therapeutics
Aug 24, 2026
Maintained: Buy
Price Target: $675
Current: $512.88
Upside: +31.61%
AnaptysBio
Aug 24, 2026
Maintained: Buy
Price Target: $75 → $70
Current: $58.44
Upside: +19.78%
Amylyx Pharmaceuticals
Aug 18, 2026
Maintained: Buy
Price Target: n/a
Current: $38.15
Upside: -
Bright Minds Biosciences
Aug 16, 2026
Maintained: Buy
Price Target: n/a
Current: $77.03
Upside: -
NervGen Pharma
Aug 13, 2026
Maintained: Buy
Price Target: n/a
Current: $2.00
Upside: -
Metagenomi Therapeutics
Aug 11, 2026
Maintained: Buy
Price Target: n/a
Current: $1.21
Upside: -
Axsome Therapeutics
Aug 10, 2026
Maintained: Buy
Price Target: $300 → $315
Current: $205.40
Upside: +53.36%
Mirum Pharmaceuticals
Aug 10, 2026
Maintained: Buy
Price Target: $140
Current: $96.72
Upside: +44.75%
Ardelyx
Aug 6, 2026
Maintained: Buy
Price Target: $13 → $10
Current: $3.74
Upside: +167.38%
Viridian Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: n/a
Current: $24.02
Upside: -
Aug 6, 2026
Maintained: Buy
Price Target: n/a
Current: $60.56
Upside: -
Aug 6, 2026
Maintained: Buy
Price Target: n/a
Current: $24.20
Upside: -
Aug 4, 2026
Rated: Buy
Price Target: $90
Current: $86.73
Upside: +3.30%
Aug 4, 2026
Rated: Buy
Price Target: $275 → $300
Current: $254.47
Upside: +17.89%
Jul 30, 2026
Maintained: Buy
Price Target: $90
Current: $71.06
Upside: +26.65%
Jul 29, 2026
Maintained: Buy
Price Target: n/a
Current: $47.46
Upside: -
Jul 28, 2026
Maintained: Buy
Price Target: $57 → $58
Current: $48.87
Upside: +18.68%
Jul 28, 2026
Maintained: Buy
Price Target: n/a
Current: $25.99
Upside: -
Jul 17, 2026
Maintained: Buy
Price Target: n/a
Current: $49.33
Upside: -
Jun 14, 2026
Maintained: Buy
Price Target: n/a
Current: $12.56
Upside: -
May 14, 2026
Maintained: Buy
Price Target: n/a
Current: $11.36
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $7.33
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $3.25
Upside: -
Nov 5, 2025
Maintained: Buy
Price Target: n/a
Current: $4.66
Upside: -
Jul 19, 2024
Rated: Hold
Price Target: n/a
Current: $21.33
Upside: n/a
Oct 17, 2023
Downgraded: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
May 24, 2023
Maintained: Hold
Price Target: $40
Current: $154.31
Upside: n/a
Oct 10, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $12.01
Upside: n/a
Oct 1, 2020
Reiterated: Buy
Price Target: n/a
Current: $145.75
Upside: n/a